To evaluate whether imatinib affects the ability of slanDCs to promote the tumoricidal potential of NK cells, DCs from healthy donors were cultured for 6 h in the presence of imatinib. Subsequently, slanDCs were cocultured with immunomagnetically purified autologous CD56 þ CD3À NK cells in the presence of LPS for 18 h. Then, NK cells were separated from adherent DCs by resuspension, and cytotoxic activity of NK cells was analyzed against the CML cell line K-562 in a 4 h 51 Cr-release assay. As illustrated in Figure 2e , imatinib did not inhibit the capacity of slanDCs to improve the tumor-directed cytotoxicity of NK cells.
Taken together, we demonstrated that imatinib does not impair maturation and cytokine expression of slanDCs from healthy donors or CML patients in complete cytogenetic remission under treatment. Functional data revealed that the capacity of slanDCs to promote proliferation and differentiation of CD4 þ T cells and to improve the tumoricidal potential of NK cells is not influenced by imatinib. These results provide evidence that imatinib as a potent therapeutic agent for CML patients does not impair the effectivity of native human myeloid blood DCs as important regulators of innate and adaptive antitumor immunity. Furthermore, our findings encourage the design of clinical trials combining immunotherapy and imatinib. This effort is also inspired by other reports, 4, 9 particularly by a recent study demonstrating that peptide vaccination induced immunological and clinical responses in imatinib-treated CML patients. We read with interest the recent article by Behl et al., 1 showing a beneficial effect of high absolute lymphocyte counts after induction chemotherapy on overall survival and leukemia-free survival (LFS) in patients with acute myelogenous leukemia. The authors' speculation that the effect was related to an antileukemic role of reconstituting natural killer (NK) cells is plausible, as T-cell immunological reconstitution is profoundly impaired in patients undergoing intensive chemotherapy. 2 Our own investigations of the antileukemia activity of human leukocyte antigen (HLA)-matched and autologous NK cells in myelogenous leukemia after allogeneic hematopoietic stem cell transplantation (SCT) also support a role for autologous NK cells in myeloid malignancies. 3, 4 The missing self-hypothesis 5 does not explain the antileukemic activity of autologous or allogeneic HLA-matched NK cells, as myelogenous leukemia cells always retain HLA class I antigen expression. 6 However, we and others found that HLA-matched or autologous NK cells can induce leukemia cell elimination in vitro and in vivo through ligands of NK-activating receptors on myeloid leukemia cells, suggesting a role of NK cells in graft-versus-leukemia (GVL) activity in HLAidentical sibling SCT. 3, 7 The in vivo potential of NK cells in HLA-matched SCT has been recently described by Savani et al. 4 In this study of factors associated with early molecular remission in CML after T-celldepleted allogeneic SCT, we made two critical observations: first, the day-30 NK count (NK30) was associated with outcome, predicting for survival and early molecular remission. Second, CD34 cell dose and NK30, but not day-30 CD3 þ cell count, were predictors of transplant outcome and CD34 cell dose correlated with day-30 NK counts. The conclusion was that higher transplanted CD34 cell doses may improve outcomes by increasing early recovery of NK cells. These observations suggest that GVL activity early after HLA-matched SCT may be exerted more by NK cells than by T cells. However, it is not obvious how such NK cells would exert GVL, since 30 days after transplant most NK cells are likely to be more immunoregulatory than cytotoxic (CD56 bright CD16 cells). 8, 9 We hypothesize that early NK cells exert non-classical antileukemia activity. We found that interleukin (IL)-2 stimulation of granulocyte colony-stimulating factor-mobilized CD34 þ cells generates NK and myeloid cells with strong cell-to-cell contact antiproliferative activity (but weak cytotoxic activity) against myeloid leukemia cell lines. [10] [11] [12] Kinetic studies have shown that the antiproliferative effect of CD34 þ cells on myeloid cell lines begins about 48 h (data not shown) following IL-2 stimulation, before CD56 antigen acquisition (Figure 1) . Thus, we speculate that cytokine-stimulated CD34 þ cells have an inhibitory effect on leukemia proliferation, which is present during IL-2-or IL-15-induced lymphoid and myeloid commitment toward NK cells and early monocytes. This antiproliferative effect may compensate for deficient cytolytic activity against myeloid leukemia cells. It will be of interest to determine whether early recovering NK cells after SCT or after induction chemotherapy possess similar properties and to explore the GVL potential of this cytostatic function. Ando et al.
1 report a case of acute myeloid leukaemia (AML) of donor cell origin following cord blood transplantation. This is the third such recent case. 2, 3 At least two other cases, in Japan and France (S Mizutani and E Gluckman, personal communication), have been observed but as yet unpublished. A similar phenomenon has been recorded previously in more than 20 cases following conventional bone marrow transplantation. 4 In both situations, leukemia of donor cell origin will be under-
